Table 2.

Maximum percent decrease in FEV₁ after exercise from two different baselines: postdose/pre-challenge and predose.^*

	Visit postdose/pre-challenge at baseline			Visit pre-dose at baseline
Patients	Screening visit (placebo)	DB-placebo	DB-levalbuterol	Screening visit (placebo)	DB-placebo	DB-levalbuterol
1	−42.6	−24.3	−0.9	−41.7	−25.8	0.0
2	−40.8	−54.1	−21.3	−40.8	−55.7	−1.5
3	−31.0	−31.6	−6.8	−31.2	−33.0	0.0
4	−30.0	−44.9	−0.2	−28.1	−42.8	0.0
5	−27.4	−30.4	−4.5	−27.8	−29.5	0.0
6	−26.4	−16.2	−12.0	−27.5	−18.3	−4.0
7	−25.6	−20.4	−8.8	−26.5	−20.8	0.0
8	−23.4	−16.3	−7.4	−21.0	−17.1	−5.7
9	−23.2	0.0	0.0	−24.6	0.0	0.0
10	−22.9	−24.1	−4.0	−21.5	−20.0	0.0
11	−21.2	−8.0	−10.6	−22.5	−7.3	−5.3
12	−21.3	−14.8	−0.5	−20.3	−15.5	0.0
13	−20.5	−17.6	0.0	−16.9	−18.3	0.0
14	−22.4	−11.7	−4.6	−20.7	−8.9	−0.6
15	−19.0	−12.7	−5.8	−19.4	−13.4	−2.5
Mean (SD)	−26.5 (7.0)	−21.8 (14.0)	−5.8 (5.8)	−26.0 (7.3)	−21.8 (14.2)	−1.3 (2.1)

^*DB-placebo and DB-levalbuterol indicates the placebo or levalbuterol treatment, respectively, during the double-blind period of the study.